Fetal death, miscarriage linked to genetic mutation

February 26, 2003

COLUMBUS, Ohio - Scientists have discovered that the genetic mutation that causes the childhood cancer retinoblastoma routinely triggers fetal death and miscarriage in laboratory animals by disrupting the normal functions of the placenta, a finding that may force researchers to reevaluate the powerful Rb gene and the role it plays in causing cancer.

Gustavo Leone

"This is one of those discoveries where our team was in the right place at the right time and we ran with a hunch," says Gustavo Leone, a geneticist at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and senior author of the study.

Twenty years ago, the Rb gene was the first to be identified as a tumor suppressor gene - meaning when it functions normally, it is able to keep cells from growing out of control. Scientists believe it is a critical player in the cell cycle, turning "on" and "off" at key stages in cell division. It is also believed to be linked to two key processes that frequently malfunction when cancer begins - proliferation (cell growth), and apoptosis (cell death).

"There is some sort of problem in the Rb pathway in virtually every cancer we know," says Leone.

Although Rb mutation is most readily linked with retinoblastoma, Leone and his colleagues had been following its impact in laboratory animals. Scientists have known for several years that mice with two defective Rb genes invariably develop massive neural and structural problems and die half way through their gestational period. But the question has always remained: why those particular defects? What was going on?

As it turns out, the answer eluded them because they had simply been looking in the wrong place.

Writing in the February 27 issue of Nature, Leone and colleagues from the United States and Canada demonstrated that fetal death is actually due to mutation-induced structural changes in the placenta caused by the gene mutation.

"The evidence lay right in front of us the whole time, but it was a matter of shifting focus," says Leone.

The discovery can be traced back to a casual but critical observation by a member of the research team that had been working with mice genetically engineered to lack a protein called E2F3, a key link in the downstream Rb pathway. Alain de Bruin, a veterinary pathologist working in Leone's laboratory, noticed that the tiny mouse placentas with the E2F3 deficiency looked different. Rather than dismiss it, he shared his observation with Leone.

" It would have been so easy to ignore something that you don't know very much about," says Leone, "but I thought the consequences could be significant."

Leone had been studying the Rb pathway for some time, and knew that deletion of E2F3 as well as two of the proteins that direct Rb function ( p57 and p27) both led to cell proliferation and defects in the placenta. He wondered if the absence of Rb itself would lead to the same thing.

To test their hypothesis, they compared the placentas of normal mice with those carrying Rb mutation. Normal placentas are composed of three distinct layers: the labyrinth, spongiotrophoblast and trophoblast giant cell layers. While all are important in terms of fetal development, the labyrinth may be the most critical; that is the place where the most intimate exchange of nutrients, oxygen and waste takes place between the fetus and the mother.

They found that in normal placentas, the labyrinth is a neat and well-ordered environment, with maternal blood sinusoids and trophoblasts evenly dispersed among fetal blood cells. In the Rb defective placentas, however, the trophoblasts had grown wildly out of control, clumping together and disrupting the smooth and even matrix of fetal and maternal cells necessary for proper embryonic growth and development (see illustration).

Further tests revealed more discrete differences between the two sets of mice. In the Rb deficient group, proliferation of the trophoblasts reduced by almost 40 percent the area of nutrient transfer surface between mother and fetus, a finding reinforced by tests that showed a marked decrease in the amount of essential fatty acids in the mutated mice compared with the normal ones. The fatty acids - essential for growth - cannot be synthesized by the fetus and must be provided by the mother through the placenta.

" It was pretty clear that the lack of Rb had crippled normal placental function," says Leone. "The embryos died from anemia and massive cell death in the nervous system around two weeks into their gestational period. What we needed to do at that point was to prove that it was due to placental malfunctioning. In other words, could we create an Rb mutated mouse with a normal placenta?"

It turns out they could.

Through two separate and very different experimental approaches, they demonstrated that Rb deficient embryos with normal placentas were able to be carried to term and be born alive. In addition, those embryos lacked many of the neurological or developmental problems associated with Rb mutation. These "rescued" mice had been largely cured of anemia and showed no abnormal cell death in the brain.

Through embryonic manipulation, Michael Robinson, a member of the OSUCCC as well as a professor in the department of pediatrics at Ohio State, created a tetraploid embryo - one which had twice the number of normal chromosomes - with with normal Rb function that, when aggregated with an Rb mutant diploid embryo, generated a fetus that was Rb deficient but supplied by a normal placenta (see graphic).

" These animals were able to be brought to term, because the normal placenta -with normal Rb functioning - helped them grow properly," says Robinson. "This experiment was the first that gave us evidence that embryos lacking a functional Rb gene can be brought to birth if given a normal placenta."

The research team came to the same conclusion in another experiment where they were able to isolate the Rb-placental-defect relationship through genetic engineering.

Still, even though the researchers were able to successfully rescue the mutated mice, Leone points out that all the mice brought to term died shortly after birth because developmental defects in their skeletal muscle and nervous systems prevented them from breathing properly.

" This leads us to conclude that there are some very complex relationships between mutation and growth that we still need to explore," says Leone. "It may be that Rb is not the mastermind of all of the functions we originally thought. I believe we may have uncovered strong evidence to suggest that Rb function is critical to the proliferative process, but may be more loosely aligned with apoptosis, or cell death. We may want to re-examine how Rb works in other areas. What we have learned is that in cancer, as in many areas of our lives, while we have to work with very tiny structures, we cannot forget the big picture."
The research included work from Ohio State collaborators Lizhao Wu, Harold Saavedra, Anthony Trimboli, Jana Opavska, Pamela Wilson, Michael Ostrowski, Thomas Rosol and Michael Weinstein, as well as support from faculty at the University of Cincinnati and the University of Calgary.

The project was funded by grants from the National Cancer Institute, the National Institutes of Health, the National Center for Research Resources and the Canadian Institutes of Health Research.

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a network of interdisciplinary research programs comprising over 200 investigators in 12 colleges and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute on the Ohio State campus. OSUCCC members conduct research on the prevention, detection, diagnosis and treatment of cancer, generating over $75 million annually in external funding.

Ohio State University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.